Intercept Announces New Findings From Long-term Extension Of Landmark POISE Trial In PBC Showing Importance Of Biomarkers Beyond ALP At AASLD The Liver Meeting 2023
Portfolio Pulse from Benzinga Newsdesk
Intercept Pharmaceuticals, a subsidiary of Alfasigma S.p.A., has announced new data from a sub-analysis of the Phase 3 POISE trial, which evaluates the impact of obeticholic acid (OCA) on liver biomarkers GGT and ALP in the treatment of primary biliary cholangitis (PBC). The findings suggest that OCA can reduce GGT and ALP levels below thresholds that predict improved outcomes, including survival, in PBC. The data will be presented at the American Association for the Study of Liver Diseases' The Liver Meeting® in Boston.
November 10, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intercept Pharmaceuticals' new data from the Phase 3 POISE trial suggests that OCA can reduce liver biomarkers GGT and ALP in PBC treatment, potentially improving patient outcomes. This could boost the company's reputation and market position.
The new data from the Phase 3 POISE trial suggests that Intercept Pharmaceuticals' OCA can reduce liver biomarkers GGT and ALP in PBC treatment, potentially improving patient outcomes. This could enhance the company's reputation and market position, potentially leading to increased demand for its products and a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100